Page last updated: 2024-12-07

3,4-dihydroxypyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-Dihydroxypyridine is a naturally occurring compound that has been isolated from various sources, including the roots of the plant *Salvia officinalis*. It exhibits a wide range of biological activities, including antioxidant, anti-inflammatory, and antimicrobial properties. 3,4-Dihydroxypyridine is a potent inhibitor of the enzyme xanthine oxidase, which is involved in the production of uric acid, and is therefore being investigated as a potential therapeutic agent for the treatment of gout. Its antioxidant activity stems from its ability to scavenge free radicals, protecting cells from oxidative damage. Its anti-inflammatory properties are attributed to its ability to inhibit the production of pro-inflammatory cytokines. Furthermore, 3,4-dihydroxypyridine has been shown to possess antimicrobial activity against a range of bacteria and fungi. The unique chemical structure and biological activity of 3,4-dihydroxypyridine make it an interesting target for further research and development, particularly in the field of drug discovery.'

3-hydroxy-4(1H)-pyridone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID105085
CHEMBL ID310900
CHEBI ID29053
CHEBI ID28630
SCHEMBL ID141070
MeSH IDM0050640

Synonyms (41)

Synonym
CHEMBL310900
3-hydroxypyridine-4-one
CHEBI:29053
pyridine-3,4-diol
CHEBI:28630 ,
3-hydroxy-4-pyridone
brn 0110211
3,4-pyridinediol
C02932
C03927 ,
3,4-dihydroxypyridine
3-hydroxypyridin-4(1h)-one
10182-48-6
1121-23-9
3-hydroxy-4h-pyrid-4-one ,
3-hydroxy-4(1h)-pyridinone
4(1h)-pyridinone, 3-hydroxy-
3,4-dihydroxypyridin
AKOS006350882
FT-0650310
3-hydroxy-1h-pyridin-4-one
A800461
AKOS005264864
5-21-12-00105 (beilstein handbook reference)
unii-uw0c50cu4h
uw0c50cu4h ,
SCHEMBL141070
AM85417
W-204429
Q-101867
3-hydroxy-4(1h)-pyridone
mfcd01691806
DTXSID50274234
3,3-dihydroxypyridine
Q27891533
3,4-pyridinediol;pyridine-3,4-diol;3-hydroxy-4(1h)-pyridinone
BCP32266
C14003
AS-56719
SB52682
CS-0155544

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cattle and goats in Australia lack the ability to totally degrade 3-hydroxy-4(1H)-pyridone, also known as 3,4-dihydroxy pyridine (3,4 DHP), the ruminal metabolite of mimosine, a toxic aminoacid present in the leguminous shrub Leucaena leucocephala."( Successful transfer of DHP-degrading bacteria from Hawaiian goats to Australian ruminants to overcome the toxicity of Leucaena.
Jones, RJ; Megarrity, RG, 1986
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters of the drug determined by the intravenous route indicate that CP117 has a plasma clearance of 10."( Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
Choudhury, R; Epemolu, RO; Hider, RC; Rai, BL; Singh, S, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
"hr via the intravenous and oral routes, respectively, thus indicating that the systemic bioavailability of the drug is < 10%."( Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
Choudhury, R; Epemolu, RO; Hider, RC; Rai, BL; Singh, S, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" A dose-response study suggested that basic pyridinones are relatively more effective at lower doses when compared with N-alkyl hydroxypyridinones."( Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
Hider, RC; Khodr, HH; Liu, ZD; Lu, SL, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
4-pyridonesAny pyridone that is pyridin-4-one or its derivatives by substitution of one of more of the hydrogens.
dihydroxypyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
mimosine biosynthesis08

Bioassays (7)

Assay IDTitleYearJournalArticle
AID29379Acid dissociation constant (pKa2) was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID29366Acid dissociation constant (pKa1) was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID26572log K2 value of the compound1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID26615Acid dissociation constant was determined1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID26823Acid dissociation constant was determined1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID28931Logarithm of cumulative stability constant was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID26567log K1 value of the compound1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (15.87)18.7374
1990's18 (28.57)18.2507
2000's12 (19.05)29.6817
2010's21 (33.33)24.3611
2020's2 (3.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.17 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (4.62%)6.00%
Case Studies1 (1.54%)4.05%
Observational0 (0.00%)0.25%
Other61 (93.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]